 PALO ALTO, Calif., Jan. 25, 2021 GLOBE NEWSWIRE -- BridgeBio Pharma, Inc. Nasdaq: BBIO the Company, we or BridgeBio announced today that it intends to offer, subject to market conditions and other factors, 400 million aggregate principal amount of convertible senior notes due 2029 the notes in a private offering the offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended the Securities Act. In connection with the offering, the Company expects to grant the initial purchasers an option to purchase up to an additional 60 million aggregate principal amount of notes. 